Last reviewed · How we verify

NCT05809973: StrokeVIS

The Oslo Study of Visual Impairment After Stroke (StrokeVIS)

Completed Last updated 1 October 2025
What this trial tests

trial testing VISA tool in Stroke, Acute in 127 participants. Completed in 31 December 2024.

Timeline
15 November 2021
Primary endpoint
21 May 2024
31 December 2024

Quick facts

Lead sponsorOslo University Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment127
Start date15 November 2021
Primary completion21 May 2024
Estimated completion31 December 2024
Sites1 location across Norway

Drugs / interventions tested

Conditions studied

Sponsor

Oslo University Hospital

Who can join

18 and older, any sex, with Stroke, Acute. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Longitudinal, prospective, single-center observational study of visual impairment after stroke. Population: Patients admitted with acute ischemic stroke at the Regional Stroke Unit at Oslo University Hospital who are assessed to not have more serious neurological deficits than to be eligible for a prospective observational study of visual impairment. National Institute of Health Stroke Scale (NIHSS) will be used for screening of the patients eligible for the study with cut off of NIHSS 20. Based on the number of patients admitted to our center to include 120 patients in the StrokeVIS study. The study aims are: 1. To determine the prevalence of visual impairment in stroke patients in the acute phase and after 3 months. 2. To compare visual impairment in those treated with EVT and those not. 3. To determine the sensitivity and specificity of the Vision Screening Assessment (VISA) tool for detection of visual impairment in stroke patients. 4. To assess possible association between brain MRI lesions and visual impairment in stroke patients in the acute phase. 6\) To assess any cognitive deficits at 3-month follow-up that could impact visual function. Inclusion criteria: 1. Acute ischemic stroke and NIHSS \< 20 2. Age ≥18 years. 3. Written informed consent of the patient or oral informed consent witnessed by a doctor. Exclusion criteria: 1. NIHSS \< 20 2. No willingness and ability of the patient to participate in all baseline and follow-up examinations. Duration of study participation: 3 months.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Validation of the Vision Impairment Screening Assessment in acute stroke care: a prospective diagnostic accuracy study.
    Ryan SJ, Jørstad AEL, Moe MC, Skjelland M, et al · · 2026 · PMID 42213811 · DOI 10.1093/esj/aakag053

Verify or expand the search:

Other recruiting trials for Stroke, Acute

Currently open trials in the same condition.

Other Oslo University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05809973.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing